Company Profile

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE484.30-7.1 (-1.44 % )
PREV CLOSE (Rs.) 491.40
OPEN PRICE (Rs.) 492.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 90116
TODAY'S LOW / HIGH (Rs.)482.05 492.70
52 WK LOW / HIGH (Rs.)84.4 504
NSE484.65 -7.1 (-1.44 % )
PREV CLOSE(Rs.) 491.75
OPEN PRICE (Rs.) 490.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 484.65 (73 )
VOLUME 2001627
TODAY'S LOW / HIGH(Rs.) 482.00 492.55
52 WK LOW / HIGH (Rs.)84.33 504.15

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.25
TTM EPS (Rs.) 17.82
P/E Ratio 27.18
Book Value (Rs.) 41.32
Face Value (Rs.) 2
MCap (Rs. in Mn) 259876.54
Price/Earning (TTM) 22.54
Price/Sales (TTM) 5.45
Price/Book (MRQ) 11.72
PAT Margin (%) 9.55
ROCE (%) 14.41
Incorporation Year : 2005

Management Info :

Malempati Venugopala Rao - Chairman - Managing Director

Registered Office :

Address : Plot No.21, J N Pharma City,Parawada, ,
Vishakhapatnam,
Andhra Pradesh-531021

Phone : 0891 3061222

Website : www.lauruslabs.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
30Apr04-30-2021$Laurus Labs reports around 3-fold jump in Q4 consolidated net profit Laurus Labs reports around 3

Laurus Labs has reported results for fourth quarter and year ended March 31, 2021.

The company has reported around 3-fold jump in its net profit at Rs 292.78 crore for the quarter under review as compared to Rs 112.53 crore for the same quarter in the previous year. Total income of the company increased by 69.04% at Rs 1,404.46 crore for Q4FY21 as compared Rs 830.85 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported around 3-fold jump in its net profit attributed to the owners at Rs 296.68 crore for the quarter under review as compared to Rs 110.15 crore for the same quarter in the previous year. Total income of the company increased by 68.46% at Rs 1,416.45 crore for Q4FY21 as compared Rs 840.82 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported around 4-fold jump in its net profit at Rs 956.11 crore as compared to Rs 267.05 crore for the previous year. Total income of the company increased by 71.09% at Rs 4,796.04 crore for year under review as compared to Rs 2,803.15 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported around 4-fold jump in its net profit attributed to the owners at Rs 983.58 crore as compared to Rs 255.27 crore for the previous year. Total income of the company increased by 70.46% at Rs 4,837.17 crore for year under review as compared to Rs 2,837.64 crore for year ended March 31, 2020.

Laurus Labs has reported results for fourth quarter and year en..
30Apr04-30-2021$Laurus Labs rises on reporting around 3-fold jump in Q4 consolidated net profit Laurus Labs rises on reporti

Laurus Labs is currently trading at Rs. 460.25, up by 2.20 points or 0.48% from its previous closing of Rs. 458.05 on the BSE.

The scrip opened at Rs. 458.05 and has touched a high and low of Rs. 466.50 and Rs. 451.30 respectively. So far 75173 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 482.65 on 29-Apr-2021 and a 52 week low of Rs. 84.40 on 18-May-2020.

Last one week high and low of the scrip stood at Rs. 482.65 and Rs. 450.65 respectively. The current market cap of the company is Rs. 24850.06 crore.

The promoters holding in the company stood at 27.45%, while Institutions and Non-Institutions held 24.24% and 48.31% respectively.

Laurus Labs has reported around 3-fold jump in its net profit at Rs 292.78 crore for fourth quarter ended March 31, 2021 as compared to Rs 112.53 crore for the same quarter in the previous year. Total income of the company increased by 69.04% at Rs 1,404.46 crore for Q4FY21 as compared Rs 830.85 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported around 3-fold jump in its net profit attributed to the owners at Rs 296.68 crore for fourth quarter ended March 31, 2021 as compared to Rs 110.15 crore for the same quarter in the previous year. Total income of the company increased by 68.46% at Rs 1,416.45 crore for Q4FY21 as compared Rs 840.82 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported around 4-fold jump in its net profit at Rs 956.11 crore as compared to Rs 267.05 crore for the previous year. Total income of the company increased by 71.09% at Rs 4,796.04 crore for year under review as compared to Rs 2,803.15 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported around 4-fold jump in its net profit attributed to the owners at Rs 983.58 crore as compared to Rs 255.27 crore for the previous year. Total income of the company increased by 70.46% at Rs 4,837.17 crore for year under review as compared to Rs 2,837.64 crore for year ended March 31, 2020.

Laurus Labs is currently trading at Rs. 460.25, up by 2.20 poin..
29Apr04-29-2021$Laurus Labs board approves interim dividend payment Laurus Labs board approves i

Laurus Labs has informed that the Board of Directors of the Company in their meeting held on April 29, 2021 have approved for the payment of 3rd interim dividend of 80 Paise (40%) per equity share of Rs 2 each, for the Financial Year 2020-21. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed May 12, 2021 as Record Date for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 19, 2021. The Board Meeting commenced at 1.30 PM and concluded at 2.30 PM.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs has informed that the Board of Directors of the Com..
29Apr04-29-2021$Laurus Labs informs about investor presentation Laurus Labs informs about in

Laurus Labs has informed that it has enclosed the presentation to the Investors/ Analysts on the Standalone and Consolidated Financial Results of the Company for the Quarter and year ended March 31, 2021, for the Investors/ Analysts call scheduled on April 30, 2021, which was already intimated on April 26, 2021. The presentation is also being uploaded on the website of the Company www.lauruslabs.com.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs has informed that it has enclosed the presentation..
29Apr04-29-2021$Allotment of Equity shares under ESOP Allotment of Equity shares u
Inter alia, approved the following: 1. Approved for the payment of 3rd interim dividend of80 Paise (40?/o) per equity share ofRs.2/- each, for the Financial Year 2020-21. 2. Re-appointment of Mrs. Aruna Rajendra Bhinge as an Independent Director for second term ( 4) Re-appointment of Dr. Rajesh Koshy Chandy as an Independent Director for second term Recommended to the shareholders, the re-appointment of Dr. Rajesh Koshy Chancly as an Independent Director for a further term period of five years (second term) with effect from July 27, 2021. (5) ESOP Scheme 2021 Recommended to the shareholders for the approval of ESOP Scheme 2021 of the Company, to create, offer, issue and allot at any time to or for the benefit of such person(s) who are in the employment of the Company, including Directors of the Company whether whole time or otherwise whether working in India or out of India, under a Scheme titled "LAURUS LABS EMPLOYEE STOCK OPTION SCHEME 2021" (hereinafter referred as the "ESOP Scheme, 2021" or "Scheme"), options exercisable into equity shares being not more than 1,000,000 (One Million Only) equity shares of Rs.2 each of the Company at an exercise price of 25% discount on the Fair Market Value of Share on the date of Grant of Options under ESOP Scheme 2021, in one or more tranches and on such terms and conditions as may be fixed or determined by the Board/Committee in accordance with the provisions of the Companies Act 2013 or SBEB Regulations or other provisions of the laws as may be prevailing and applicable at that time, each option granted being exercisable for one equity share of the Company." (6) 16th Annual General Meeting of the Company Approved the Notice for convening the 16th Annual General Meeting (AGNI) of the Company on July 15, 2021 at 03.00 PM (IST) through Video Conference and Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from July 09, 2021 to July 15, 2021 (both days inclusive) for taking record of the Members of the Company for the purpose of 16th Annual General Nleeting.
Inter alia, approved the following: 1. Approved for the pa..
Financials More
Rs. in Millions
QTR Mar 21 ANNUAL 21
Net Profit2927.89561.1
Gross Profit 3963.8 12746.3
Operating Profit 4681.715371.9
Net Sales 13987.447687.2
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
NGL Fine-Chem (BSE)
 1679.60 (4.62%)
M.Cap ( in Cr)
1037.66
Ajanta Pharma (BSE)
 2010.70 (3.51%)
M.Cap ( in Cr)
17398.94
Solara Active Pharma (BSE)
 1748.00 (3.11%)
M.Cap ( in Cr)
6280.52
Themis Medicare (BSE)
 479.85 (8.78%)
M.Cap ( in Cr)
440.91
Abbott India (BSE)
 16220.00 (0.16%)
M.Cap ( in Cr)
34466.37
Shareholding Pattern More
NON-INSTITUTION 48.31 %
PROMOTERS 27.45 %
MUTUAL FUNDS/UTI 2.05 %
FI/BANKS/INSURANCE 0.01 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes